
Opinion|Videos|May 27, 2025
Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
Author(s)Neal Shore, MD, FACS
Exploring the impact of ultra-sensitive PSA testing on treatment decisions for metastatic hormone-sensitive prostate cancer, enhancing patient outcomes and care efficiency.
Advertisement
Episodes in this series

Comparison of PSA Thresholds
Key Themes:
- Comparison between ultra-low threshold (<0.02 ng/mL) and traditional thresholds (<0.1 or <0.2 ng/mL)
- Sensitivity and specificity considerations
- Prognostic value of different PSA cutoff points
Expert Insights:
- Dr Shore discussed the differences between the ultra-low PSA threshold and more conventional thresholds commonly used in clinical practice.
The conversation addressed the sensitivity, specificity, and potential prognostic significance of various PSA cutoff points.
Advertisement
Related to this article

Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.

VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.

Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.

Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.

An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.

Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.

Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants 510(k) clearance to OpenFlo urinary catheter
2
FDA grants fast track designation to VIR-5500 for mCRPC
3
Variation in PSMA PET Adoption for Prostate Cancer Care
4
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
5
